

Improving the
Management
of HIV Disease®
2008

An Advanced CME Course in HIV Pathogenesis, Antiretrovirals,
and Other Selected Issues in HIV Disease Management

Tuesday, May 13, 2008

Information and online registration are available at
www.iasusa.org

Washington, DC

16th YEAR of CME Courses Sponsored by the International AIDS Society-USA

Improving the
Management
of HIV Disease®
2008

An Advanced CME Course in HIV Pathogenesis, Antiretrovirals,
and Other Selected Issues in HIV Disease Management

Tuesday, May 13, 2008
Renaissance Washington, DC Hotel
999 Ninth Street, NW
Washington, DC 20001

COURSE CHAIRS:

Henry Masur, MD
Clinical Professor of Medicine
George Washington University
School of Medicine
Washington, DC, and Bethesda, MD

Michael S. Saag, MD
Professor of Medicine
Director, Division of Infectious Diseases
Director, Center for AIDS Research
The University of Alabama at Birmingham
Birmingham, AL



PRELIMINARY AGENDA

- 7:30 AM** Registration
- 8:15** **Welcome and Introduction**
Henry Masur, MD and Michael S. Saag, MD
- 8:30** **The HIV Epidemic in Washington, DC**
Shannon Hader, MD
- 8:50** **Glucose, Type II Diabetes, and HIV**
Steven K. Grinspoon, MD
8:50 - Basic Science
9:20 - Clinical Implications
- 9:50** **Question-and-Answer Period and Break**
- 10:30** **The Pathogenesis of Fat Redistribution: What HIV Clinicians Need to Know**
Fred R. Sattler, MD
- 11:00** **Question-and-Answer Period**
- 11:10** **Emerging Investigational Antiretroviral Drugs**
Scott M. Hammer, MD
- 11:40** **Strategies for Antiretroviral Failure: Case-based Panel Discussion**
Michael S. Saag, MD
- 12:25 PM** **Question-and-Answer Period and Break**
- 1:00** **Hosted Working Lunch**
Managing Depression: What Do You Do Before Calling the Psychiatrist?
Glenn J. Treisman, MD, PhD
- 1:45** **Question-and-Answer Period and Break**
- 2:10** **Current Issues in Renal Toxicities**
Lynda A. Szczech, MD
- 2:40** **What's New in the Opportunistic Infection Guidelines?
A Case-based Panel Discussion**
Henry Masur, MD
- 3:25** **New Approaches to Treatment of Hepatitis C Virus in HIV-coinfected Persons**
David L. Thomas, MD, MPH
- 3:55** **Question-and-Answer Period**
- 4:15** **Closing Remarks**

COURSE FACULTY

COURSE CHAIRS

Henry Masur, MD
Clinical Professor of Medicine
George Washington University
School of Medicine
Washington, DC, and Bethesda, MD

Michael S. Saag, MD
Professor of Medicine
Director, Division of Infectious Diseases
Director, Center for AIDS Research
The University of Alabama at Birmingham
Birmingham, Alabama

COURSE SPEAKERS

Shannon Hader, MD
Director
HIV/AIDS Administration
Department of Health
Washington, District of Columbia

Scott M. Hammer, MD
Professor of Medicine
Columbia University College of Physicians and Surgeons
Chief, Division of Infectious Diseases
Columbia Presbyterian Medical Center
New York, New York

Steven K. Grinspoon, MD
Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts

Fred R. Sattler, MD
Professor of Medicine and Biokinesiology
Division of Infectious Diseases
University of Southern California School of Medicine
Los Angeles, California

Lynda A. Szczech, MD
Associate Professor
Duke University Medical Center
Durham, North Carolina

David L. Thomas, MD, MPH
Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland

Glenn J. Treisman, MD, PhD
Associate Professor
Director, AIDS Psychiatry Services
Johns Hopkins Medical Institutions
Baltimore, Maryland

PLEASE TYPE OR PRINT CLEARLY.

ID No. IAS-USA #12246
 SUE SMITH, MD
 425 CALIFORNIA ST., STE. 1450
 SAN FRANCISCO, CA 94104

IAS-USA ID NUMBER (if applicable)

FIRST NAME MI LAST NAME

TITLE/POSITION (must provide)

INSTITUTION/ORGANIZATION (no abbreviations please)

ACADEMIC DEGREE/LICENSE (check all that apply):

MD DO International Equivalent (specify) _____

PA NP RN PharmD

Other (specify) _____

SPECIALTY _____

MAILING ADDRESS Work Home

CITY _____ STATE _____ ZIP _____

PHONE Work Home _____

FAX Work Home _____

E-MAIL ADDRESS (for registration confirmation)

Do you wish to receive IAS-USA announcements and other information at this e-mail address? Yes No

We do not sell our mailing list to other organizations or commercial companies.

Please select **ONE** handout format, which you will receive onsite:

Printed, bound syllabus Syllabus on CD-ROM

(Note: power and wireless internet connections will not be available for viewing the CD-ROM in the sessions.)

Do you work for a commercial company? Yes No

IF YES, PLEASE PROVIDE NAME OF COMPANY; see "Who Should Attend."

You will be sent additional course/registration information.

REGISTRATION FEES

Include full payment with this form.

For additional registrants, please photocopy this form.

\$50 on or before April 22

\$65 after April 22

If you wish to include a donation* please indicate here. Thank you!

Total: \$ _____

*IAS-USA is exempt from tax under section 501(c)(3) of the Internal Revenue Code. Your tax-deductible donation will be used to distribute topics in HIV Medicine[®] Internationally.

↓ DETACH HERE ↓

WEB



AMERICAN ACADEMY OF FAMILY PHYSICIANS CREDIT

This activity has been reviewed and is acceptable for up to 6.75 Prescribed credits by the American Academy of Family Physicians.

NURSING CONTACT HOURS CREDIT DESIGNATION STATEMENT

Southeast AIDS Training and Education Center is an approved provider of continuing nursing education by the Georgia Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Contact hours will be awarded based on attendance at entire training program and submission of completed evaluation forms. This course is approved for 7.0 contact hours.

REGISTRATION

Early registration is strongly recommended, as attendance is limited to the first 250 registrants and these programs fill to capacity quickly.

You can register online with secure credit card payment at www.iasusa.org or mail or fax a completed registration form and payment. **The registration fee on or before April 22, 2008, is \$50; after April 22, the fee is \$65.** Registered attendees may access the course syllabus, in PDF format, on our Website (www.iasusa.org) after May 5. *Please note: The syllabus is typically more than 100 pages long and may take extra time to download.* Please submit requests for cancellation or substitution in writing to the IAS-USA office by April 29.

Incomplete applications (missing information, unchecked boxes, no payment included) will be returned for completion, prior to processing.

If you have not registered or have not received registration confirmation 2 weeks prior to the course, please contact us to confirm that seating is still available.

For general information and questions, please contact:

International AIDS Society-USA
 425 California Street, Suite 1450
 San Francisco, CA 94104-2120
 Phone: (415) 544-9400 Fax: (415) 544-9402
 E-mail: registration2008@iasusa.org

Visit our Website to register online, to confirm your registration, and for course updates: www.iasusa.org

GRANT SUPPORT

This program is supported by educational grants from several commercial companies. In the interest of an objective, balanced, and scientifically rigorous program, the International AIDS Society-USA seeks funding from companies with competing products. These companies have no input into or control over any aspect of the activity, including program content or selection of faculty.

Substantial Grant Support

- Bristol-Myers Squibb
- Tibotec Therapeutics
- Abbott Laboratories
- Gilead Sciences
- Merck & Co., Inc.
- Pfizer Global Pharmaceuticals

Generous Grant Support

- GlaxoSmithKline

Grant support from additional companies will be announced as they are confirmed.

ASSESSMENT OF NEEDS

Rapid advances in HIV disease management require the ongoing attention of HIV practitioners involved in HIV medicine. This course will address the implications of new information on strategies for HIV management. Information will be presented through a mix of didactic lectures and clinically relevant cases developed by an expert faculty of HIV/AIDS clinicians and researchers.

Some medical specialty societies, including the HIV Medicine Association and the American Academy of HIV Medicine, and some state licensing boards may require that members earn a certain number of HIV/AIDS *AMA PRA Category 1 Credits™*. This course may contribute toward those requirements.

COURSE OBJECTIVES

- Upon completion of the course, participants will be able to:
- Outline the pathogenesis of glucose intolerance in HIV-infected patients, recognize risk factors, and develop management strategies for Type II Diabetes as a metabolic complication of HIV and its therapies
 - Design antiretroviral strategies that consider current data on:
 - The management of complicated failure, use of resistance testing, and the role of newly approved drugs in antiretroviral regimens
 - The status of investigational antiretroviral drugs
 - Renal disease as a complication of HIV and its therapies
 - Discuss the latest treatment issues in opportunistic infections and opportunistic infections and immune reconstitution inflammatory syndrome
 - Formulate appropriate strategies for managing mental health issues in HIV-infected patients
 - Describe the incidence, diagnosis, and management of hepatitis C virus coinfection with HIV, including the status of investigational agents
 - Choose effective treatment regimens to manage lipodystrophy as a toxicity of HIV and its therapies

CONFLICTS OF INTEREST

Information regarding conflicts of interest is obtained from all parties with control over the activity content (ie, co-chairs, faculty, and IAS-USA staff), and any conflicts of interest of those parties are resolved prior to the activity being delivered. Financial affiliations of all those parties is published in the course syllabus.

WHO SHOULD ATTEND

This course is designed for physicians who are actively involved in the medical care of people with HIV/AIDS, specifically those who:

- Have a solid, working knowledge of HIV disease management
- Provide comprehensive or specialty care for at least 10 patients with HIV/AIDS or are involved in HIV/AIDS clinical trials or investigations
- Have completed at least 10 hours of CME in the area of HIV/AIDS medicine in the past 2 years

This course is also relevant for nonphysician practitioners involved in HIV/AIDS patient care, including nurse practitioners and other nursing professionals, physician assistants, pharmacists, and others.

Representatives and employees of commercial companies (pharmaceutical, diagnostic, medical products, advertising, insurance, investment, communications firms, etc) must contact the International AIDS Society-USA regarding registration procedures.

CME ACCREDITATION STATEMENT

The International AIDS Society-USA is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

The International AIDS Society-USA designates this educational activity for a maximum of 7.0 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Washington, DC

Make checks or money orders payable to International AIDS Society-USA.
 Charge to my credit card: Visa MasterCard AmEx
 Card Number (Visa, MasterCard, or American Express only) _____

Expiration Date ____/____/____

AUTHORIZED SIGNATURE ON CARD _____

CARDHOLDER'S NAME _____

Please mail or fax this registration form and payment to:
 International AIDS Society-USA
 Registration - Washington, DC
 425 California Street, Suite 1450
 San Francisco, CA 94104-2120
 Phone (415) 544-9400; Fax (415) 544-9402

Applications with the early registration fee must be received by April 22. Pre-registration closes on May 6.

Check here if you are in need of any special assistance at the course. Please notify us at least 2 weeks in advance, if possible, so that we may make the necessary arrangements. Please describe: _____

Check here to order a vegetarian meal. _____

Check here if you have other dietary restrictions. (Please note: additional fees may apply for special meals, eg, kosher meals) _____

Explain: _____